Cassava Sciences Dirección
Dirección controles de criterios 2/4
El CEO de Cassava Sciences' es Remi Barbier , nombrado en May 1998, tiene una permanencia de 25.92 años. compensación anual total es $6.26M, compuesta por 19% salario y 81% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.09% de las acciones de la empresa, por valor de $27.43M. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 12.9 años, respectivamente.
Información clave
Remi Barbier
Chief Executive Officer (CEO)
US$6.3m
Compensación total
| Porcentaje del salario del CEO | 19.0% |
| Permanencia del CEO | 25.9yrs |
| Participación del CEO | 3.1% |
| Permanencia media de la dirección | 3.6yrs |
| Promedio de permanencia en la Junta Directiva | 12.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Oct 17
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Jul 04We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate
Mar 05Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Nov 19Cassava Sciences begins extension study of Alzheimer's drug simufilam
Oct 13Cassava Sciences Stock: Huge Returns Or Catastrophic Losses
Sep 29Cassava Sciences: Trying To Manage Expectations
Sep 21Cassava Sciences reaches over five-month high on rising volumes
Sep 09Cassava Sciences Looks As Good Of A Purchase As Ever
Sep 03Cassava Sciences stock jumps 10% after director buys $860K shares
Aug 26Cassava Sciences rally continues as stock up 39%
Aug 17Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results
Aug 11Cassava Sciences GAAP EPS of -$0.48 misses by $0.06
Aug 03We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Aug 03Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug
Jul 27Cassava Sciences And Alzheimer's Disease: A Precipitious Path
Jun 10Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate
May 31Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait
Apr 193 Key Points To Remember About Cassava Sciences
Apr 07Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences
Mar 31Cassava Sciences: Why The Stock Is Rangebound
Feb 28The FDA Deals Another Blow To Cassava Sciences' Bears
Feb 11Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity
Feb 02INmune Bio, The Biotech In My Stable For After Cassava Sciences
Jan 17Cassava Sciences, Inc. - The Short Squeeze Has Started
Jan 06Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam
Dec 30Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
Dec 28Cassava Sciences Stock: Here We Go Again
Dec 21Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing
Dec 02Cassava Sciences Gets Underway Putting Simufilam To The Test
Nov 24Cassava Sciences: Data Rules!
Nov 17Cassava Sciences' Hypothesis Raises Doubts
Nov 08Cassava Sciences Stock: Massive Potential Marred By Controversy
Nov 01Cassava Sciences: Welcome To The Casino
Oct 25Has Cassava Sciences Put Out The Fire For Now?
Sep 28Cassava Sciences: Medical History In The Making
Sep 21Cassava Sciences: One Doubtful Drug For One Doubtful Indication
Sep 15We Think Cassava Sciences (NASDAQ:SAVA) Can Afford To Drive Business Growth
Sep 14More On Cassava Sciences' Controversy
Sep 04Cassava Sciences Likely To Survive Latest Attack On Alzheimer's Drug, But Caveat Emptor
Aug 265 Reasons Cassava Sciences Could Still Be The Most Undervalued Stock In The Market
Jul 27Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$6m | US$1m | -US$97m |
| Sep 30 2023 | n/a | n/a | -US$95m |
| Jun 30 2023 | n/a | n/a | -US$90m |
| Mar 31 2023 | n/a | n/a | -US$83m |
| Dec 31 2022 | US$1m | US$1m | -US$76m |
| Sep 30 2022 | n/a | n/a | -US$71m |
| Jun 30 2022 | n/a | n/a | -US$61m |
| Mar 31 2022 | n/a | n/a | -US$46m |
| Dec 31 2021 | US$2m | US$975k | -US$32m |
| Sep 30 2021 | n/a | n/a | -US$21m |
| Jun 30 2021 | n/a | n/a | -US$13m |
| Mar 31 2021 | n/a | n/a | -US$9m |
| Dec 31 2020 | US$936k | US$920k | -US$6m |
| Sep 30 2020 | n/a | n/a | -US$5m |
| Jun 30 2020 | n/a | n/a | -US$4m |
| Mar 31 2020 | n/a | n/a | -US$4m |
| Dec 31 2019 | US$1m | US$899k | -US$5m |
| Sep 30 2019 | n/a | n/a | -US$4m |
| Jun 30 2019 | n/a | n/a | -US$4m |
| Mar 31 2019 | n/a | n/a | -US$6m |
| Dec 31 2018 | US$934k | US$875k | -US$7m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$10m |
| Mar 31 2018 | n/a | n/a | -US$11m |
| Dec 31 2017 | US$2m | US$875k | -US$12m |
Compensación vs. Mercado: La compensación total de Remi($USD6.26M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.47M).
Compensación vs. Ingresos: La compensación de Remi ha aumentado mientras la empresa no es rentable.
CEO
Remi Barbier (63 yo)
25.9yrs
Permanencia
US$6,263,038
Compensación
Mr. Remi Barbier founded Cassava Sciences, Inc. (formerly known as Pain Therapeutics, Inc.). since May 1998 and has been its President and Chief Executive Officer since May 1998 and served as its Principal...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 25.9yrs | US$6.26m | 3.09% $ 27.5m | |
| Chief Financial Officer | 5.5yrs | US$2.99m | 0.054% $ 478.8k | |
| Senior VP | 1.5yrs | US$1.27m | 0% $ 0 | |
| Chief Medical Officer | 3.3yrs | US$2.97m | 0.0069% $ 61.7k | |
| Senior Vice President of Technology | no data | sin datos | sin datos | |
| Senior Vice President of Technical Operations | no data | sin datos | sin datos | |
| Senior Vice President of Regulatory Affairs | 1.4yrs | sin datos | sin datos | |
| Senior Vice President of Neuroscience | 4yrs | sin datos | sin datos |
3.6yrs
Permanencia media
61yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de SAVA se considera experimentado (3.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 25.9yrs | US$6.26m | 3.09% $ 27.5m | |
| Lead Independent Director | 25.6yrs | US$546.16k | 2.96% $ 26.3m | |
| Independent Director | 16.3yrs | US$438.42k | 0.0028% $ 24.6k | |
| Independent Director | 25.8yrs | US$438.42k | 0.019% $ 169.5k | |
| Member of Scientific Advisory Board | 9.5yrs | US$558.31k | sin datos | |
| Independent Director | 2.8yrs | US$546.16k | 0.81% $ 7.2m | |
| Independent Director | 21.1yrs | US$546.16k | 0.029% $ 261.8k | |
| Independent Director | less than a year | US$474.50k | 0% $ 0 | |
| Independent Director | less than a year | US$474.50k | 0% $ 0 | |
| Independent Director | less than a year | US$474.50k | 0% $ 0 |
12.9yrs
Permanencia media
67.5yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de SAVA son experimentados ( 12.9 años antigüedad media).